DE60013417D1 - Verfahren zur selektion von fxr-rezeptormodulatoren - Google Patents

Verfahren zur selektion von fxr-rezeptormodulatoren

Info

Publication number
DE60013417D1
DE60013417D1 DE60013417T DE60013417T DE60013417D1 DE 60013417 D1 DE60013417 D1 DE 60013417D1 DE 60013417 T DE60013417 T DE 60013417T DE 60013417 T DE60013417 T DE 60013417T DE 60013417 D1 DE60013417 D1 DE 60013417D1
Authority
DE
Germany
Prior art keywords
fxr
selection
receptor modulators
methods
fxr receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60013417T
Other languages
English (en)
Other versions
DE60013417T2 (de
Inventor
M Forman
Haibo Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of DE60013417D1 publication Critical patent/DE60013417D1/de
Application granted granted Critical
Publication of DE60013417T2 publication Critical patent/DE60013417T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Genetics & Genomics (AREA)
DE60013417T 1999-03-26 2000-03-24 Verfahren zum screenen von fxr-rezeptormodulatoren Expired - Fee Related DE60013417T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12633499P 1999-03-26 1999-03-26
US126334P 1999-03-26
PCT/US2000/007836 WO2000057915A1 (en) 1999-03-26 2000-03-24 Method of affecting cholesterol catabolism using nuclear bile acid receptor

Publications (2)

Publication Number Publication Date
DE60013417D1 true DE60013417D1 (de) 2004-10-07
DE60013417T2 DE60013417T2 (de) 2005-09-15

Family

ID=22424256

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60013417T Expired - Fee Related DE60013417T2 (de) 1999-03-26 2000-03-24 Verfahren zum screenen von fxr-rezeptormodulatoren
DE60029029T Expired - Fee Related DE60029029T2 (de) 1999-03-26 2000-03-24 Screenen nach FXR-Rezeptormodulatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60029029T Expired - Fee Related DE60029029T2 (de) 1999-03-26 2000-03-24 Screenen nach FXR-Rezeptormodulatoren

Country Status (7)

Country Link
EP (1) EP1165135B1 (de)
JP (1) JP2004510682A (de)
AT (2) ATE274921T1 (de)
AU (1) AU780658B2 (de)
CA (1) CA2368234A1 (de)
DE (2) DE60013417T2 (de)
WO (1) WO2000057915A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
EP1317542A2 (de) * 2000-09-16 2003-06-11 LION Bioscience AG Kernrezeptor l66 und verfahren zu deren verwendung
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
EP1465882B1 (de) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
DK1734970T3 (en) 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
JP4928260B2 (ja) * 2004-04-23 2012-05-09 武田薬品工業株式会社 新規スクリーニング方法
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
MX2008000141A (es) 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
MX2009007728A (es) 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
US8114862B2 (en) 2008-11-19 2012-02-14 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
ES2620451T3 (es) 2009-05-28 2017-06-28 Exelixis Patent Company Llc Moduladores de los LXR
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
PL2758060T3 (pl) * 2011-09-19 2018-04-30 ETH Zürich Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II
CA2876706A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
CA3028207A1 (en) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP2781217A1 (de) * 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
WO2018049362A1 (en) * 2016-09-12 2018-03-15 Massachusetts Institute Of Technology Transcriptional sensor for bile acids in bacteroides thetaiotaomicron

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294376B1 (en) * 1993-02-05 2001-09-25 Merrill Overturf Cholesterol 7-alpha hydroxylase expression regulation
EA199800279A1 (ru) * 1995-10-11 1999-04-29 Талариа Терапьютикс, Инк Липосомные композиции и способы их применения
WO1997035195A1 (en) * 1996-03-19 1997-09-25 The Salk Institute For Biological Studies In vitro methods for identifying modulators of members of the steroid/thyroid superfamily of receptors
ATE278958T1 (de) * 1996-03-20 2004-10-15 Dyax Corp Reinigung des gewebe plasminogenaktivators (tpa)

Also Published As

Publication number Publication date
CA2368234A1 (en) 2000-10-05
WO2000057915A1 (en) 2000-10-05
DE60029029D1 (de) 2006-08-03
AU780658B2 (en) 2005-04-07
ATE274921T1 (de) 2004-09-15
EP1165135A1 (de) 2002-01-02
EP1165135B1 (de) 2004-09-01
JP2004510682A (ja) 2004-04-08
DE60013417T2 (de) 2005-09-15
AU3917300A (en) 2000-10-16
DE60029029T2 (de) 2007-06-14
ATE330632T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
DE60013417D1 (de) Verfahren zur selektion von fxr-rezeptormodulatoren
WO2003030612A3 (en) Methods for modulating activity of the fxr nuclear receptor
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
NO20070898L (no) Diversitetsinnfelling av kodebiter ved plassering og blanding
DE60132624D1 (de) Verfahren zum verteilen von werbung unter verwendung einer eingebetteten medien-abspielerseite
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
ATE298248T1 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
NO20050717L (no) Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon
NO960767D0 (no) Protocadherinproteiner og deres anvendelse
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
IL124652A0 (en) Screening assay for compounds stimulating somatostatin and insulin production
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
DE59801882D1 (de) Verfahren zur synchronisierten darstellung von netz-inhalten
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
DE60029429D1 (de) Verfahren und zusammensetzungen zur überwachung der modifikation von natürlichen bindungspartners
DE60210253D1 (de) Verfahren zur identifizierung von modulatoren des cholesterinrückwärtstransportes
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
DE60102539D1 (de) Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Sphingosinkinasen
DE60328932D1 (de) Verfahren und Reaktor zur Durchführung von Rezeptor-Ligand Bindungsreaktionen
WO1998022500A3 (en) Modulation of interactions between myosin and integrins
DE60302263D1 (de) Verfahren zur Durchführung von Rezeptor-Ligand Bindungsreaktionen
DK1007649T3 (da) Fremgangsmåder til screening for interaktioner mellem transkriptionsfaktor og coaktivator

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee